No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.
www.cohance.comNo one on the platform currently holds COHANCE.NS.
No tracked institution reports a position in COHANCE.NS as of their last filing.
No one on the platform has traded COHANCE.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.3% | 20.1% | — | — | — | |
| Rev. Growth % | 89.4% | 17.6% | ||||
| Profit Margin % | 7.9% | 24.8% | ||||
| Free Cash Flow Margin % | 6.0% | 15.6% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $23.2B | +2.8% | $5.73 | $4.19–$7.08 | — | 6 |
| 2028 | $27.9B | +20.2% | $9.83 | $7.23–$11.80 | — | 7 |
| 2029 | $31.8B | +14.0% | $13.85 | $10.69–$16.55 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.60 | $-0.62 | -2.5% |
| 2026-05-12 | $1.14 | $0.90 | -21.1% |
| 2026-02-12 | $2.69 | $0.97 | -63.8% |
| 2025-11-12 | $1.55 | $1.90 | +22.6% |
| 2025-08-13 | $1.59 | $1.60 | +0.6% |
| 2025-05-28 | $3.40 | $3.50 | +2.9% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| COHANCE.NSCohance Lifesciences Limited | $423.60 | -3.77% | $162.1B | — |
| AJANTPHARM.BOAjanta Pharma Limited | $3506.25 | -0.87% | $437.4B | — |
| AJANTPHARM.NSAjanta Pharma Limited | $3510.40 | -0.65% | $438.6B | — |
| ASTRAZEN.NSAstraZeneca Pharma India Limited | $6695.50 | -1.02% | $167.4B | — |
| COHANCE.BOCohance Lifesciences Limited |
| $423.60 |
| -4.07% |
| $161.7B |
| — |
| ERIS.NSEris Lifesciences Limited | $1310.10 | -3.35% | $181.6B | — |
| IPCALAB.BOIpca Laboratories Limited | $1934.30 | -1.66% | $494.4B | — |
Source: Financial Modeling Prep · peers by sector/industry